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Abstract
Background:  Mutations in the core promoter and precore regions of the hepatitis B virus (HBV)
genome, notably the double substitution (AGG to TGA) at nt positions 1762-1764 in the core
promoter, and the precore stop codon mutation G to A at nt 1896, can often explain the anti-HBe
phenotype in chronic carriers. However, the A1896 mutation is restricted to HBV isolates that
have T at nt 1858. The double substitution at positions 1762-1764 has been described to occur
preferentially in patients infected with strains showing C instead of T at nt 1858.
Results:  HBV DNAs from 29 anti-HBe Brazilian samples were characterized by nucleotide
sequencing of PCR products from precore region. Among them, 18 isolates presented C at nt 1858
(mostly genotype A strains). The 11 remaining isolates (genotypes D and F) had T1858. The stop
codon mutation at nt 1896 was found in seven isolates (24% of the total and 63% of the isolates
that had T1858). The frequency of the double substitution at positions 1762-1764 was surprisingly
low (20%) among C1858 isolates. An association between A1896 and TGA 1762-1764 mutations
was observed among genotype D isolates: these showed either none of the two mutations or both.
Furthermore, strains mutated at positions 1896 and/or 1762-1764 also presented an elevated
number of other, less common substitutions in the core promoter and precore regions.
Conclusions:  The data reported here are not in accordance with some reports from other parts
of the world. In half of the isolates, none of the mutations previously described could explain the
anti-HBe phenotype.
Background
Chronic hepatitis B virus (HBV) infection, defined by the
persistence of the surface antigen (HBsAg) in serum for
longer than six months, may lead to a wide spectrum of
liver disease, including asymptomatic carrier state,
chronic active hepatitis (CAH), cirrhosis, and hepatocel-
lular carcinoma (HCC). Hepatitis B e antigen (HBeAg) is
considered a marker for viral replication, whereas the
presence of anti-HBe antibodies often indicates a low
level of viral production. Seroconversion from HBeAg to
anti-HBe normally correlates with improvement of liver
disease. However, HBV variants have been described
with mutations in the precore region that prevent HBeAg
synthesis, despite continuing production of infectious
virions. The most common of these mutations is a G to A
substitution at nucleotide (nt) 1896, that prevents the
production of HBeAg by introducing a premature stop
codon into the open reading frame (ORF) of the precore
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region [1,2]. Several studies have associated the muta-
tion A1896 with an exacerbation of the clinical symp-
toms of liver disease caused by HBV [3,4]. In other
studies, however, such an association has not been ob-
served [5,6,7]. The occurrence of the A1896 mutation de-
pends upon the nucleotide (C or T) at position 1858, that
forms a base pair with nt 1896 in the pregenomic RNA
loop. The presence of a C at position 1858 precludes the
G to A mutation at nt 1896 as this would destabilize the
stem-loop structure of the RNA encapsidation signal [8].
The presence of the A1896 mutation is thus restricted to
genotypes that have a T at nt 1858, as is the case for gen-
otypes B, C, D, and E. Genotype A usually shows a C at
this position [9] while genotype F may present a T or a C
[10]. HBV genotypes are not uniformly distributed
around the world, and the A1896 mutation has been
found to be more prevalent in geographic regions where
genotypes B, C and D are predominant, such as Asia and
the Mediterranean area, and less prevalent in North
America and Europe where genotype A is commonly
found [11,12]. In South America, where genotypes A, D,
and F have been found [13,14,15], the frequency of the
mutation is unknown.
Besides the A1896 mutation, a number of point muta-
tions leading to initiation failure or premature termina-
tion, as well as deletions and insertions of nucleotides
inducing frameshifts, have been detected in the precore
region [5,7].
Regulation of transcription and expression of the pre-
core and core genes has been extensively studied
[16,17,18]. Mutations in the core promoter, notably the
double mutation at positions 1762 and 1764 changing
AGG to TGA, have been suggested to mediate down-reg-
ulation of HBeAg production [19]. Such mutations, able
to prevent or reduce the transcription of precore mRNA
and HBe synthesis [20,21,22], have been found in anti-
HBe positive chronic carriers.
In this study, we identify the mutations present in the
precore and core promoter regions of HBV isolates (gen-
otypes A, D, and F) derived from anti-HBe positive Bra-
zilian patients.
Results
Precore stop codon mutation A1896
Nucleotide sequences of a 200-bp fragment, from the
precore start codon at nt 1814, were determined for 29
HBV strains derived from anti-HBe positive chronic car-
riers. By phylogenetic analysis (Fig. 1), 17 isolates be-
longed to genotype A, nine to genotype D, and three to
genotype F. These numbers were representative of the
genotype distribution existing in Brazil. All isolates from
genotype A showed C at position 1858 and, as expected
in this case, G at nt 1896, independently of the clinical
status of the patients (Table 1I). This C1858:G1896 pattern
was also observed in one genotype F isolate derived from
an asymptomatic individual. The 11 remaining isolates
had T1858. Four of them, from genotype D, presented
the T1858:G1896 pattern. The seven others (five from gen-
otype D and two from genotype F) showed the 1896 G to
A substitution leading to a stable T1858:A1896 base pair-
ing and introducing a stop codon into the ORF of the pre-
core. In the group of 11 isolates with T1858 in which the
A1896 mutation could emerge (Table 1I), 6/7 mutated
isolates were from patients with chronic liver disease
(four with cirrhosis, two with CAH) whereas 3/4 isolates
showing the T1858:G1896 pattern were from asymptomat-
ic carriers (p = 0.09). This revealed a tendency towards a
correlation between A1896 mutation and liver disease.
Table I: Occurrence of the precore stop codon mutation in HBV isolates.
Number of patients
Nucleotides
at positions Precore stop
Genotype 1858:1896 codon mutation
With cirrhosis With CAH Asymptomatic Total
AC : G N o 6 4 7 1 7
DT : G N o 0 1 3 4
T:A Yes 2 2 1 5
FC : G N o 0 0 1 1
T:A Yes 1 1 0 2
Total 9 8 12 29BMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
Core promoter mutation TGA 1762-1764
In all, only seven out of 29 (24%) HBV isolates presented
the precore stop codon mutation at nt 1896. Due to the
low frequency of the A1896 mutation, we decided to in-
vestigate the existence of other mutations in a region of
the genome covering the core promoter and precore re-
gions, as well as the core protein initiation codon. Nucle-
otide sequencing was thus expanded in the 19 isolates
(10 from genotype A, seven from genotype D, and two
from genotype F) for which a fragment extending from
nt 1720 to nt 1919 was successfully PCR amplified. Of
these isolates, 14 did not show the A1896 stop mutation.
No deletion or insertion was observed in any of the 19
isolates. Table 2II indicates that only six isolates (A5, A6,
D2-D5) showed the double substitution changing AGG to
TGA at positions 1762-1764 in the core promoter region,
which might explain the anti-HBe seroconversion of the
patients infected with isolates not showing the A1896
stop codon mutation. The triplet TGA was observed in 2/
10 isolates belonging to genotype A, 4/7 D isolates, and
0/2 F strains. Remarkably, twelve isolates (A1-A4, A7-
A10, D1, D6-D7, and F1) presented neither the A1896
mutation nor the 1762-1764 double substitution.
Conversely, all four D isolates (D2-D5) mutated at posi-
tion 1896 were also mutated at positions 1762-1764. No
association was found between liver damage and muta-
tion of the AGG 1762-1764 motif (Table 2II).
Other mutations
Point mutations other than those studied above were
then sought in the core promoter and precore regions.
For clarity, these mutations will be hereafter called un-
common point mutations in contrast to the A1896 G to A
and 1762-1764 AGG to TGA substitutions referred as
common point mutations . Table 2II (last column) shows
the number of uncommon point mutations, with respect
to a consensus sequence based on the genotype A isolates
without common point mutations. Consequently, the
number of substitutions is overestimated for isolates of
genotypes D and F, since the consensus sequence for
comparison is based on genotype A strains and genotype
A-specific substitutions are also counted for isolates of
genotypes D and F. In a general manner, it is not easy to
differentiate between uncommon point mutations and
the considerable natural variation in HBV sequences.
Even so, it was very interesting to note that the number
of uncommon point mutations was lower in the HBV iso-
lates without common point mutations. This was evident
for genotype A, since isolates A1-A4 and A7-A10 (without
common point mutations) showed 0-4 uncommon point
mutations (mean, 0.9), whereas isolates A5 and A6 (with
Table II: Demographic and clinical data of the anti-HBe positive patients.
Nucleotides at positions No. of substitutionsa
Genotype Patient Age/Sex Clinical status 1762-1764 1858 1896 CPMs UPMs
A A1 55/M Cirrhosis AGG C G 0 0
A2 41/F Cirrhosis AGG C G 0 0
A3 45/M Cirrhosis, HCC AGG C G 0 1
A4 40/F Cirrhosis AGG C G 0 0
A5 10/F Asymptomatic TGA (mutant) C G 1 6
A6 52/M CAH TGA (mutant) C G 1 8
A7 38/M CAH AGG C G 0 2
A8 54/M Cirrhosis AGG C G 0 0
A9 52/M CAH AGG C G 0 4
A10 39/M Asymptomatic AGG C G 0 0
D D1 36/M CAH AGG T G 0 2
D2 54/F Asymptomatic TGA (mutant) T A (stop) 2 7
D3 56/F CAH TGA (mutant) T A (stop) 2 13
D4 35/M Cirrhosis TGA (mutant) T A (stop) 2 5
D5 55/M CAH TGA (mutant) T A (stop) 2 8
D6 47/M Asymptomatic AGG T G 0 6
D7 53/M Asymptomatic AGG T G 0 6
F F1 10/M Asymptomatic AGG C G 0 7
F2 35/M CAH AGG T A (stop) 1 8
aNumber of common (CPMs) and uncommon (UPMs) point mutations (see text) in a 200-bp genome segment, from nt 1720 to nt 1919BMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
one common point mutation) had 6 and 8 uncommon
point mutations (mean, 7), respectively. In genotype D,
the means were 4.7 for isolates (D1, D6, D7) without
common point mutations, and 8.5 for isolates (D2-D5)
mutated at both positions 1896 and 1762-1764.
Figure 2 shows the alignment of the nucleotide sequenc-
es from nt 1720 to nt 1919. It can be seen that several re-
gions were conserved through all sequences, including
stretches that are essential for viral replication, i.e. the
AT-rich region, extending from nt 1789 to nt 1795, and
Figure 1
Phylogenetic tree of 37 HBV isolates, constructed with the neighbor-joining method, and based on 200 nucleotides (positions
1814-2013). Capital letters A, D, and C designate the respective genotype groupings. Bootstrap values were calculated from
100 replicates and the numbers above 60 are shown. Isolates A1 to A17, D1 to D9, and F1 to F3 are from this work. Their
nucleotide sequences have been deposited in the Genbank database under accession numbers AF389988 to AF390016. The
other isolates are designated by their Genbank accession numbers.
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Figure 2
Alignment of partial nucleotide sequences of HBV isolates derived from anti-HBe carriers. The consensus sequence (based on
wild-type genotype A strains) is indicated at the top. Dots represent the same nucleotides as in the consensus sequence. Let-
ters at the left represent the genotypes of the strains. The AT-rich region (nt 1789-1795) and the direct repeat DR1 (nt 1824-
1834) are underlined. The two common point mutations, i.e. the double substitution in the core promoter (nt 1762-1764) and
the precore stop codon mutation (nt 1896), are indicated by arrows. The other substitutions constitute the uncommon point
mutations. The initiation codons for precore and core proteins are also shown. HVR: Hypervariable region (nt 1751-1755).
Core promoter
_HVR_ mutation
1730 1740 1750 1760 1770 1780
CONSENSUS TGTTTAAGGACTGGGAGGAGCTGGGGGAGGAGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCA
A 1,2,4,8,10 ......................................................................
A 3 ......................................................................
A 5 .......A............T............C........T.A.........................
A 6 .......A............T............C........T.A.........................
A 7 .....................................................C................
A 9 ......................................................................
D 1 ......................................................................
D 2 .......A............T............C...A....T.A........C................
D 3 .......A............T.......T..C.G...A....T.A.T.A....C................
D 4 ....................T.....................T.A........C................
D 5 .......A............T............C...A....T.A........C................
D 6,7 .......A............T................A...............C................
F 1 .A..................T.T...............................................
F 2 .......A............T.............C..................C..............T.
1800 1810 Precore 1830 1840 1850
CONSENSUS TAAATTGGTCTGCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCA
A 1,2,4,8,10 ......................................................................
A 3 ......................................................................
A 5 ...................T..T...............................................
A 6 ...................T..T...............................................
A 7 ..........C...........................................................
A 9 ...................T..T...............................................
D 1 ............................................................T.......T.
D 2 ............................................................T.......T.
D 3 ...........................T................................T.......T.
D 4 ............................................................T.......T.
D 5 ............................................................T.......T.
D 6,7 ............................................................T.......T.
F 1 ............TT.........................................T....T.........
F 2 ............TT..............................................T.......T.
Stop
mutation
1870 1880 1890 Core 1910
CONSENSUS CTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGGACATTGACCCTTATA
A 1,2,4,8,10 ............................................................
A 3 ..T.........................................................
A 5 ..T.........................................................
A 6 ..T.........................A..............T................
A 7 ............................................................
A 9 ..T.........................A...............................
D 1 ............................................................
D 2 ....................................A.......................
D 3 ....................................A............C..........
D 4 ....................................A...............T.......
D 5 ....................................A..A....................
D 6,7 ............................................................
F 1 ............................................................
F 2 ....................................A.......................BMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
the direct repeat DR1 (nt 1824 to 1834). The following
substitutions appeared to be linked to the genotype (al-
though not all the isolates of a determined genotype nec-
essarily showed the mutation): G to A 1721 (found in
genotype F), G to A 1757 (D), C to T 1802 (F), G to T 1803
(F), A to T 1850 (D and F), and C to T 1858 (D and F).
Furthermore, a number of uncommon point mutations
were observed that were not linked to any genotype, sev-
eral of which have been previously characterized. These
mutations were rarely observed in the sequences without
common point mutations. Typically, substitutions in the
hypervariable region from nt 1751 to nt 1755 [23] were
found in 6/7 genomes with common point mutations
(A5, A6, D2, D3, D5, F2) but in none of the 12 isolates
without. Further, the 1727 G to A, 1740 C to T, and 1773
T to C changes were predominantly observed among the
isolates otherwise mutated at crucial positions 1896 and/
or 1762-1764. The isolate showing the highest number of
mutations, namely D3, displayed the 1766-1768 CTT to
TTA double substitution, which has been associated with
increased transcription and viral encapsidation of prege-
nomic RNA [24,25,26], as well as a 1817 C to T change,
introducing a stop in codon 2 of the precore (Fig. 2). The
1862 G to T point mutation, which has been proposed to
contribute to the anti-HBe phenotype [27], was found in
four genotype A sequences, two of them (A5, A6) with
common point mutations and the two others (A3, A9)
without. Additionally, the 1888 G to A mutation was
present in A6 and A9 sequences. This mutation has been
proposed to increase the stability of the upper stem of the
encapsidation signal at the pregenomic RNA level [28].
Finally, the 1899 G to A substitution (codon 29 of the
precore), previously shown to enhance the pregenomic
RNA transcription [29], was found in a single isolate
(D5). As a whole, 10 sequences showed neither common
point mutation nor the 1862 G to T point mutation which
would explain the anti-HBe phenotype.
Discussion
Variants of the HBV precore region have been described
in anti-HBe, HBV DNA positive patients. The most com-
mon mutation was the G to A change at nt 1896 that cre-
ates a stop codon in the precore ORF. HBV strains
showing this mutation cannot express the HBe antigen
either on the cell membrane or in the circulation [1,2].
In a report from Asia, 90% of the HBV isolates from anti-
HBe positive, asymptomatic carriers and hepatitis pa-
tients showed the A1896 mutation [19]. Here, the muta-
tion was observed in only 7/29 (24%) HBV isolates
derived from anti-HBe positive Brazilian carriers (Table
1I). This low proportion was due in part to the fact that
the majority of our isolates had a C at nt 1858, a feature
known to preclude the stop codon mutation. In the liter-
ature, discrepancies in the frequency of the mutation can
be observed, even taking in consideration only the iso-
lates with T1858 for which the A1896 mutation may oc-
cur. Such discrepancies are observable not only between
studies performed in different geographic regions, but
also when carried out in a single country with isolates be-
longing to different genotypes. From a recent study [30],
a correlation between frequency of the mutation and
HBV genotype could be deduced: among isolates derived
from anti-HBe positive patients and showing T at nt
1858, the mutation was present in 100%. 20%, 75%, and
100% of the isolates from genotypes B, C, D, and E, re-
spectively. A proportion of 63% was obtained here, based
on the 11 isolates showing T at nt 1858 (and belonging to
genotypes D and F). In China, a country where genotypes
B and C are predominant, a high prevalence (86%) of the
mutation has been found [31]. Conversely, a study from
Sweden revealed that none of six genotype D isolates
showed the A1896 mutation during a follow-up of 17
months after anti-HBe seroconversion [32].
It has been suggested that the double substitution (AGG
to TGA) at nt positions 1762-1764 in the core promoter,
affecting the transcriptional regulation and protein ex-
pression of the precore gene, could explain why a precore
wild-type isolate may elicit an anti-HBe phenotype
[19,23,33]. Changes at positions 1762-1764 have been
described to be preferentially selected in patients infect-
ed with genotypes showing C instead of T at nt 1858 [30,
31]. In China, indeed, these core promoter changes have
been found in 91% of the isolates with C1858 compared
to 27% of the isolates with T1858 [31]. However, our data
demonstrated the presence of the double substitution at
nt 1762-1764 in only 2/11 (18%) isolates with a C1858.
Genomic characteristics other than the nucleotide
present at position 1858 must therefore be involved: a
notable difference between the Chinese study and ours is
that Brazilian isolates with C1858 were mainly from gen-
otype A, whereas most of the HBV strains circulating in
China are from genotypes B and C. Another study, ana-
lyzing core promoter mutations in isolates with T at nt
1858 and derived from East Asian HBV carriers, showed
that TGA 1762-1764 mutants were significantly more fre-
quent in genotype C isolates than in genotype B strains
[34]. Recently, Bläckberg and Kidd-Ljunggren [32] dem-
onstrated genotypic differences in core promoter and
precore sequences during seroconversion from HBeAg to
anti-HBe: in samples from patients followed before and
after seroconversion, it was found that 4/6 genotype A
isolates showed the 1762-1764 mutation during the HBe
phase. In contrast, all six genotype D isolates present in
pre- and post-seroconversion samples remained wild
type at positions 1896 and 1762-1764 [32].
An association between mutations A1896 and 1762-1764
(common point mutations) and severity of liver diseaseBMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
has been observed in several studies [3,4,29,33,35] but
not in others [5,6,7,36]. In our case, among seven geno-
type D isolates, three out of the four ones with common
point mutations derived from patients with chronic liver
disease, while two out of the three without common
point mutations derived from asymptomatic subjects
(Table 2II). However, no association between liver dis-
ease and mutation at positions 1762-1764 could be dem-
onstrated.
Conclusions
The pattern of core promoter and precore mutations of
HBVs derived from anti-HBe Brazilian carriers appeared
to be unique among those already described. First, a low
frequency (20%) of TGA 1762-1764 was noted among the
genotype A isolates. Second, a strong association be-
tween A1896 and TGA 1762-1764 mutations was ob-
served among isolates from genotype D (p < 0.05): all
isolates analyzed showed either none or both mutations
(Table 2II). Third, the common point mutations (posi-
tions 1896 and 1762-1764) were often accompanied by
other mutations, notably at positions 1727, 1740, 1773,
and in the hypervariable region (nt 1751-1755). Finally,
only two genotype A isolates that were wild type at both
positions 1896 and 1762-1764 showed other mutations
which have already been associated with the anti-HBe
phenotype. On the other hand, follow up of anti-HBe pa-
tients for measurement of viral load should be important
to better associate the replication competence of HBV
strains with anti-HBe phenotype
It has been assumed that the outcome of hepatitis B in-
fection depends on HBV genotypes [37]. Recent studies
have reported recombination events between different
genotypes of HBV, which could contribute to geographi-
cal differences in the natural history of hepatitis B
[38,39]. Central and South America are the unique re-
gions of the world where genotypes A, D and F co-circu-
late at a large scale. The presence of these three
genotypes may account for specific variations of HBV
isolates affecting the pattern of core promoter and pre-
core mutations. To date, only a few HBV genomes from
South America have been completely sequenced. Nucle-
otide sequencing of the whole genome of a large number
of strains should help to explain the single behavior of
South American HBV isolates in relation to precore-core
mutations.
Materials and Methods
Patients and serological studies
Serum samples from 29 HBV chronic carriers who were
referred between 1995 and 1999 to the Brazilian Refer-
ence Center for Viral Hepatitis, Rio de Janeiro, Brazil,
were used in this study. All patients were tested positive
for HBsAg, anti-HBe and HBV DNA, and negative for
HBeAg. Twelve patients were asymptomatic HBV carri-
ers, eight had CAH, and nine had cirrhosis.
HBsAg, HBeAg, and anti-HBe antibodies were detected
in serum samples using commercially available kits in a
microELISA system (Hepanostika kits, Organon Te-
knika, Boxtel, The Netherlands) according to the manu-
facturer's instructions.
DNA extraction and PCR assays
HBV DNA was extracted from serum using phenol-chlo-
roform after treatment with proteinase K, as reported
previously [15]. DNA samples were submitted to two
nested PCR assays, and all PCR experiments were per-
formed in a final volume of 50 µl under the following
conditions: 94°C, 30 s; 52°C, 1 min; 72°C, 2 min; 35 cy-
cles, followed by a final elongation of 7 min at 72°C. Se-
quences of the precore/ core region were amplified by
nested PCR using external primers X4 (5'-AAGGT CTT-
ACATAAGAGGAC-3', nt 1644-1663) and C2 (5'-CTAA-
CATTGAGATTCCCG AGATTGAGA-3', nt 2458-2432),
and internal primers PC1 (5'-GGCTGTAGGCA TAAATT-
GGTCTG-3', nt 1781-1803) and C3 (5'-TTGCCTGAGT-
GCAGTATGGT-3', nt 2075-2056). Core promoter region
was amplified with external primers X1 (5'-ACCTCCTT-
TCCATGGCTGC T-3', nt 1363-1382) and C2, and inter-
nal primers X4 and C3. Amplification products (10 µl)
were loaded on a 2% agarose gel, electrophoresed,
stained with ethidium bromide, and visualized under UV
light.
Nucleotide sequencing
PCR products were directly sequenced using the Au-
toload Solid Phase Sequencing system (Amersham Phar-
macia Biotech, Uppsala, Sweden). This required that the
second round of PCR was performed with one standard
and one biotinylated primer. Dideoxy sequencing reac-
tions (both strands) were performed using a fluorescent-
ly labeled primer whose nucleotide sequence was
identical to the standard primer of the second round of
PCR. The sequencing reactions were analyzed on an AL-
Fexpress automated sequencer (Amersham Pharmacia).
Computer-Assisted Sequence analysis
Nucleotide sequences were aligned using PILEUP (Wis-
consin Sequences Analysis Package GCG, Madison, WI).
A phylogenetic tree was generated by neighbor-joining
analysis of genetic distances, using the TREECON soft-
ware package for Windows [40].
Acknowledgements
The authors are grateful to the staff of the Brazilian Reference Center for 
Viral Hepatitis for the gift of the serum samples. We also thank Dr. Rachel 
Hallett for critical reading of the manuscript and English revision.BMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
References
1. Brunetto MR, Stemler M, Bonino F, Schodel F, Oliveri F, Rizzetto M,
Verme G, Will H: A new hepatitis B virus strain in patients with
severe anti-HBe positive chronic hepatitis B J Hepatol 1990,
10:258-261
2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ,
Makris A, Thomas HC: Mutation preventing formation of hepa-
titis B e antigen in patients with chronic hepatitis B infection
Lancet 1989, 2(8663):588-591
3. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A,
Serra A, Saracco G, Verme G, Will H, Bonino F: Wild-type and e
antigen-minus hepatitis B viruses and course of chronic hep-
atitis Proc Natl Acad Sci USA 1991, 88:4186-4190
4. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Ran-
done A, Abate ML, Manzini P, Capalbo M, Piantino P, Verme G, Bon-
ino F: Hepatitis B virus unable to secrete e antigen and
response to interferon in chronic hepatitis B Gastroenterology
1993, 105:845-850
5. Hsu H-Y, Chang M-H, Lee C-Y, Hsieh K-H, Ni Y-H, Chen P-J, Chen
D-S: Precore mutant of hepatitis B virus in childhood fulmi-
nant hepatitis B: an infrequent association J Infect Dis 1995,
171:776-781
6. Lindh M, Horal P, Dhillon AP, Furuta Y, Norkrans G: Hepatitis B vi-
rus carriers without precore mutations in HBeAg-negative
stage show more severe liver damage Hepatology 1996, 24:494-
501
7. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai
Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M: Hepatitis B viruses
with precore region defects prevail in persistently infected
hosts along with seroconversion to the antibody against e an-
tigen J Virol 1990, 64:1298-1303
8. Lok AS, Akarca U, Greene S: Mutations in the pre-core region of
hepatitis B virus serve to enhance the stability of the second-
ary structure of the pre-genome encapsidation signal Proc
Natl Acad Sci USA 1994, 91:4077-4081
9. Li J-S, Tong S-P, Wen Y-M, Vitvitski L, Zhang Q, Trepo C: Hepatitis
B virus genome type A rarely circulates as an HBe-minus
mutant: possible contribution of a single nucleotide in the
precore region J Virol 1993, 67:5402-5410
10. Arauz-Ruiz P, Norder H, Visoná KA, Magnius LO: Genotype F pre-
vails in HBV infected patients of hispanic origin in Central
America and may carry the precore stop mutant J Med Virol
1997, 51:305-312
11. Lindh M, Andersson AS, Gusdal A: Genotypes, nt 1858 variants,
and geographic origin of hepatitis B virus - large-scale analy-
sis using a new genotyping method J Infect Dis 1997, 175:1285-
1293
12. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R,
Guardia J: Hepatitis B virus infection: precore mutants and its
relation to viral genotypes and core mutations  Hepatology
1995, 22:1641-1647
13. Moraes MTB, Gomes SA, Niel C: Sequence analysis of hepatitis
B virus strains of genotypes A, D, and F isolated in Brazil Arch
Virol 1996, 141:1767-1773
14. Moraes MTB, Niel C, Gomes SA: A polymerase chain reaction-
based assay to identify genotype F of hepatitis B virus Braz J
Med Biol Res 1999, 32:45-49
15. Niel C, Moraes MTB, Gaspar AMC, Yoshida CFT, Gomes SA: Genet-
ic diversity of hepatitis B virus strains isolated in Rio de Janei-
ro, Brazil  J Med Virol 1994, 44:180-186
16. Gilbert S, Galameau L, Lamontagne A, Roy S, Belanger L: The hepa-
titis B virus core promoter is strongly activated by the liver
nuclear receptor fetoprotein transcription factor or by ec-
topically expressed steroidogenic factor 1 J Virol 2000, 74:5032-
5039
17. Hwang WL, Su TS: The encapsidation signal of hepatitis B virus
facilitates preC AUG recognition resulting in inefficient
translation of the downstream genes J Gen Virol 1999, 80:1769-
1776
18. Yuh CH, Chang YL, Ting LP: Transcriptional regulation of pre-
core and pregenomic RNAs of hepatitis B virus J Virol 1992,
66:4073-4084
19. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K,
Tanaka T, Miyakawa Y, Mayumi M: Hepatitis B virus with muta-
tions in th e core promoter for an e antigen-negative pheno-
type in carriers with antibody to e antigen J Virol 1994, 68:8102-
8110
20. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH: Effects of a naturally
occurring mutation in the hepatitis B virus basal core pro-
moter on precore gene expression and viral replication J Virol
1996, 70:5845-5851
21. Kidd-Ljunggren K, Oberg M, Kidd AH: The hepatitis B virus X
gene: analysis of functional domain variation and gene phyl-
ogeny using multiple sequences J Gen Virol 1995, 76:2119-2130
22. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K,
Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M: Hepatitis
B virus strains with mutations in the core promoter in pa-
tients with fulminant hepatitis Ann Intern Med 1995, 122:241-248
23. Kidd-Ljunggren K, Öberg M, Kidd AH: Hepatitis B virus X gene
1751 to 1764 mutations: implications for HBeAg status and
disease J Gen Virol 1997, 78:1469-1478
24. Baumert TF, Rogers SA, Hasegawa K, Liang TJ: Two core promotor
mutations identified in a hepatitis B virus strain associated
with fulminant hepatitis result in enhanced viral replication J
Clin Invest 1996, 98:2268-2276
25. Baumert TF, Marrone A, Vergalla J, Liang TJ: Naturally occurring
mutations define a novel function of the hepatitis B virus
core promoter in core protein expression J Virol 1998, 72:6785-
6795
26. Fang Z-L, Ling R, Wang SS, Nong J, Huang CS, Harrison TJ: HBV
core promoter mutations prevail in patients with hepatocel-
lular carcinoma from Guangxi, China J Med Virol 1998, 56:18-24
27. Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ: Precore
and core mutations in HBV from individuals in India with
chronic infection J Med Virol 1995, 45:321-325
28. Junker-Niepmann M, Bartenschlager R, Schaller H: A short cis-act-
ing sequence is required for hepatitis B virus pregenome en-
capsidation and sufficient for packaging of foreign RNA EMBO
J 1990, 9:3389-3396
29. Laskus T, Radkowski M, Nowicki M, Wang L-F, Vargas H, Rakela J:
Association between hepatitis B virus core promoter rear-
rangements and hepatocellular carcinoma Biochem Biophys Res
Commun 1998, 244:812-814
30. Lindh M, Gustavson C, Mardberg K, Norkrans G, Dhillon AP, Horal
P: Mutation of nucleotide 1,762 in the core promoter region
during hepatitis B e seroconversion and its relation to liver
damage in hepatitis B e antigen carriers  J Med Virol 1998,
55:185-190
31. Chan HLY, Hussain M, Lok AS: Different hepatitis B virus geno-
types are associated with different mutations in the core
promoter and precore regions during hepatitis B e antigen
seroconversion Hepatology 1999, 29:976-984
32. Bläckberg J, Kidd-Ljunggren K: Genotypic differences in the hep-
atitis B virus core promoter and precore sequences during
seroconversion from HBeAg to anti-HBe  J Med Virol 2000,
60:107-112
33. Inoue K, Yoshiba M, Sekiyama K, Okamoto H, Mayumi M: Clinical
and molecular virological differences between fulminant he-
patic failures following acute and chronic infection with hep-
atitis B virus J Med Virol 1998, 55:35-41
34. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P: Core pro-
moter mutations and genotypes in relation to viral replica-
tion and liver damage in East Asian hepatitis B virus carriers
J Infect Dis 1999, 179:775-782
35. Honda A, Yokosuka O, Ehata T, Tagawa M, Imazeki F, Saisho H: De-
tection of mutations in the enhancer 2/core promoter region
of hepatitis B virus in patients with chronic hepatitis B virus
infection: comparison with mutations in precore and core
regions in relation to clinical status J Med Virol 1999, 57:337-344
36. Pollicino T, Campo S, Raimondo G: PreS and core gene hetero-
geneity in hepatitis B virus (HBV) genomes isolated from pa-
tients with long-lasting HBV chronic infection Virology 1995,
208:672-677
37. Mayerat C, Mantegani A, Frei PC: Does hepatitis B virus (HBV)
genotype influence the clinical outcome of HBV infection? J
Viral Hepat 1999, 6:299-304
38. Hannoun C, Norder H, Lindh M: An aberrant genotype revealed
in recombinant hepatitis B virus strains from Vietnam J Gen
Virol 2000, 81:2267-2272BMC Microbiology (2001) 1:10 http://www.biomedcentral.com/1471-2180/1/10
39. Morozov V, Pisareva M, Groudinin M: Homologous recombina-
tion between different genotypes of hepatitis B virus Gene
2000, 260:55-65
40. Van de Peer Y, de Wachter R: TREECON for Windows: a soft-
ware package for the construction and drawing of evolution-
ary trees for the Microsoft Windows environment Comput
Applic Biosci 1994, 10:569-570
Publish with BioMedcentral and every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com